国药现代：盐酸米那普仑获得化学原料药上市申请批准

Core Viewpoint - The approval of the active pharmaceutical ingredient (API) for Minaprine Hydrochloride by the National Medical Products Administration indicates that the product meets national drug approval technical standards, allowing for production and sales in the domestic market, which will enhance the company's market competitiveness and positively impact future development [1] Group 1 - The company’s wholly-owned subsidiary, Jiangsu Weichida Pharmaceutical Co., Ltd., received the approval notice for the API Minaprine Hydrochloride [1] - Minaprine Hydrochloride is a selective serotonin and norepinephrine reuptake inhibitor (SNRI) developed by Pierre Fabre for the treatment of major depressive disorder [1] - The approval will help the company advance the integration of its product supply chain, optimize resource allocation, and improve its industry layout [1]